Make My Day - a Stroke Prevention Program

Sponsor
Karolinska Institutet (Other)
Overall Status
Recruiting
CT.gov ID
NCT05279508
Collaborator
Forte (Industry), Region Stockholm (Other)
104
1
2
29.8
3.5

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effects of a person-centered stroke prevention program implemented in primary healthcare. It is a primary prevention program aiming to reduce stroke risk and thereby prevent stroke through the enabling of lifestyle changes by introducing health beneficial engaging everyday activities promoting healthy activities and habits.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Make My Day - stroke prevention program
N/A

Detailed Description

This study is a single-blind randomized control trial with the aim to evaluate the effects of a stroke prevention program, Make My Day (MMD), in comparison to ordinary primary healthcare services for people at risk for stroke. The MMD prevention program aims to reduce modifiable stroke risk factors and the future risk of stroke by introducing health beneficial engaging everyday activities enabling lifestyle changes and promoting healthy activity patterns and habits. It also includes a mHealth application consisting of six domains for registering daily activities, experiences and behaviours: Goal achievements, Physical activity, Engaging everyday activities, Tobacco and alcohol use, Stress levels and Dietary habits, to increase health literacy and awareness of current habits and to foster self-management.

Engaging everyday activities (EEA´s) are activities the person perceives as valuable, meaningful, and purposeful, as well as provide positive feelings and a sense of participation. EEA´s are performed regularly and are a part of a person's life and depending on the activity it may or may not contribute to health.

The MMD prevention program is person-centered group interventio with health professionals as interventionists. The program starts with an individual meeting at baseline with a lifestyle analysis that includes formulating individual activity goals. Follow-up assessment is done one week after the last group session. There are 6 group sessions where each session has a pre-set theme e.g. stroke risk, engaging everyday activities, physical activity, diet, life habits and routines. Five group-sessions will be conducted over a five week period with a booster session after another five weeks, in total 10 weeks.

The MMD prevention program is a theoretically grounded, complex intervention developed in accordance with the Medical Research Council (MRC) guidelines for developing complex interventions. And in line with the MRC guidelines a feasibility and pilot study have already been conducted. To enable reduction of stroke risk and achieve healthy lifestyle habits the MMD program uses strategies based on behavioural change theories. Behaviour change derives from the interaction process between the person, the environment, and the action. Key in the MMD-program is the incorporation of health beneficial EEA´s, either to incorporate new health beneficial EEA´s or to alter current non health beneficial EEA´s.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
104 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Investigator and assessor are blinded to randomization
Primary Purpose:
Prevention
Official Title:
Make My Day: an eHealth Supported Stroke Prevention Program for Primary Health Care Preventing Stroke and Supporting Everyday Activities
Actual Study Start Date :
Apr 9, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prevention treatment group

10 week stroke prevention program with six group sessions on pre-set themes targeting modifiable stroke risk factors . The group sessions are chaired by health professionals but also consists of peer learning to support change in lifestyle habits and activity patterns and reduce stroke risk. The change process is supported with a mHealth application for daily registrering of six domains; stroke risk factors, EEA, stress and goal achievement. A lifestyle and stroke risk analysis will be performed at baseline measures, at follow up and at 12 month follow up.

Behavioral: Make My Day - stroke prevention program
A stroke prevention program within primary healthcare

No Intervention: Standard treatment group

Usual care within primary healthcare. At baseline, follow up and at 12 month follow up a lifestyle and stroke risk analysis will be conducted.

Outcome Measures

Primary Outcome Measures

  1. Risk for stroke [At baseline]

    Risk for stroke is measured with the Swedish version of the Stroke riskometer. The Stroke riskometer uses an algoritm to estimate the 5-year and 10-year stroke risk from multiple choice questions on lifestyle habits and medical history. The result is given in % for both 5-year and 10-year and higher % means higher risk.

  2. Risk for stroke [at 10week follow up]

    Risk for stroke is measured with the Swedish version of the Stroke riskometer. The Stroke riskometer uses an algoritm to estimate the 5-year and 10-year stroke risk from multiple choice questions on lifestyle habits and medical history. The result is given in % for both 5-year and 10-year and higher % means higher risk.

  3. Risk for stroke [At 12-month follow up]

    Risk for stroke is measured with the Swedish version of the Stroke riskometer. The Stroke riskometer uses an algoritm to estimate the 5-year and 10-year stroke risk from multiple choice questions on lifestyle habits and medical history. The result is given in % for both 5-year and 10-year and higher % means higher risk.

Secondary Outcome Measures

  1. Participation in engaging everyday activities [At baseline]

    Participation in engaging everyday activities measured with Canadian Occupational Performance Measure (COPM). Five activities are listed and performance and satisfaction are scored between 1-10. 1 means either not able to perform or not satisfied at all and 10 means either performs extremely well or extremely satisfied.

  2. Participation in engaging everyday activities [At 10-week follow up]

    Participation in engaging everyday activities measured with Canadian Occupational Performance Measure (COPM). Five activities are listed and performance and satisfaction are scored between 1-10. 1 means either not able to perform or not satisfied at all and 10 means either performs extremely well or extremely satisfied.

  3. Participation in engaging everyday activities [At 12-month follow up]

    Participation in engaging everyday activities measured with Canadian Occupational Performance Measure (COPM). Five activities are listed and performance and satisfaction are scored between 1-10. 1 means either not able to perform or not satisfied at all and 10 means either performs extremely well or extremely satisfied.

  4. Self rated life satisfaction [At baseline]

    Self rated life satisfaction measured with LiSat-11. A questionnaire with 11 questions with a scale 1-6. 1 means unsatisfied and 6 means very satisfied

  5. Self rated life satisfaction [At 10-week follow up]

    Self rated life satisfaction measured with LiSat-11. A questionnaire with 11 questions with a scale 1-6. 1 means unsatisfied and 6 means very satisfied

  6. Self rated life satisfaction [At 12-month follow up]

    Self rated life satisfaction measured with LiSat-11. A questionnaire with 11 questions with a scale 1-6. 1 means unsatisfied and 6 means very satisfied

  7. Self rated health [At baseline]

    Self rated health measured with EQ-5D. A questionnaire on self rated health with question on 5 health defining domain with a scale 1-3. 1 means no problems and 3 means extreme problems. Also an analog scale (VAS) ranging 0-100. 100 means best possible health and 0 means worst possible health. 1 means unsatisfied and 6 means very satisfied

  8. Self rated health [At 10-week follow up]

    Self rated health measured with EQ-5D. A questionnaire on self rated health with question on 5 health defining domain with a scale 1-3. 1 means no problems and 3 means extreme problems. Also an analog scale (VAS) ranging 0-100. 100 means best possible health and 0 means worst possible health. 1 means unsatisfied and 6 means very satisfied

  9. Self rated health [At 12-month follow up]

    Self rated health measured with EQ-5D. A questionnaire on self rated health with question on 5 health defining domain with a scale 1-3. 1 means no problems and 3 means extreme problems. Also an analog scale (VAS) ranging 0-100. 100 means best possible health and 0 means worst possible health. 1 means unsatisfied and 6 means very satisfied

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Three or more high stroke risk factors on the Stroke Risk scorecard

  • Motivated for lifestyle change

  • Motivated for participating in a digital lifestyle prevention (including user of a smartphone or tablet)

  • Between 55-75 years of age and without a diagnosis of dementia or cognitive impairment hindering participation

Exclusion Criteria:
  • Previously stroke or TIA

  • Lack of understanding the Swedish language

Other:
  • All participants may choose to interrupt their participation in the study at any time.

  • The researcher can also discontinue a participant's participation based on health issues or reasons that might jeopardize that person's safety. Reasons for interruption will be recorded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stockholms Sjukhem Stockholm Sweden

Sponsors and Collaborators

  • Karolinska Institutet
  • Forte
  • Region Stockholm

Investigators

  • Principal Investigator: Ann-Helen Patomella, PhD, Karolinska Institutet

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ann-Helen Patomella, Associate Professor, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT05279508
Other Study ID Numbers:
  • KI2020-00175
First Posted:
Mar 15, 2022
Last Update Posted:
Jun 23, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ann-Helen Patomella, Associate Professor, Karolinska Institutet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2022